ArticleNatural product reports2021
The need to innovate sample collection and library generation in microbial drug discovery: a focus on academia.
Article in Natural product reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Systematic Assessment of the Impact of Targeted Selection Methods and Environment-Mimicking Culture Conditions on Fungal Natural Product Libraries.Journal of natural products · 2026Article
- Characterization of Variation in Natural Product Production Under Chemical Elicitation Using Parallel Stable Isotope Labeling.ACS chemical biology · 2025Article
- Article
- Use of MALDI-TOF mass spectrometry and IDBac to mine for understudied bacterial genera from the environment.ISME communications · 2025Article
- Rationally Minimizing Natural Product Libraries Using Mass Spectrometry.bioRxiv : the preprint server for biology · 2024Article
- Chemical Constituents and Biological Activities ofMarine drugs · 2024Review
- Automated Microbial Library Generation Using the Bioinformatics Platform IDBac.Molecules (Basel, Switzerland) · 2022Article
- Relationship between bacterial phylotype and specialized metabolite production in the culturable microbiome of two freshwater sponges.ISME communications · 2022Article
- A taxonomically representative strain collection to explore xenobiotic and secondary metabolism in bacteria.PloS one · 2022Article
- Generation of a high quality library of bioactive filamentous actinomycetes from extreme biomes using a culture-based bioprospecting strategy.Frontiers in microbiology · 2022Article
- Article
- Evaluating the Distribution of Bacterial Natural Product Biosynthetic Genes across Lake Huron Sediment.ACS chemical biology · 2021Article
- Metabolomic Analysis of The Chemical Diversity of South Africa Leaf Litter Fungal Species Using an Epigenetic Culture-Based Approach.Molecules (Basel, Switzerland) · 2021Article
- Solid-Phase Extraction Embedded Dialysis (SPEED), an Innovative Procedure for the Investigation of Microbial Specialized Metabolites.Marine drugs · 2021Article
- A marine microbiome antifungal targets urgent-threat drug-resistant fungi.Science (New York, N.Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The question of whether culturable microorganisms will continue to be a viable source of new drug leads is inherently married to the strategies used to collect samples from the environment, the methods used to cultivate microorganisms from these samples, and the processes used to create microbial libraries. An academic microbial natural products (NP) drug discovery program with the latest innovative chromatographic and spectroscopic technology, high-throughput capacity, and bioassays will remain at the mercy of the quality of its microorganism source library. This viewpoint will discuss limitations of sample collection and microbial strain library generation practices. Additionally, it will offer suggestions to innovate these areas, particularly through the targeted cultivation of several understudied bacterial phyla and the untargeted use of mass spectrometry and bioinformatics to generate diverse microbial libraries. Such innovations have potential to impact downstream therapeutic discovery, and make its front end more informed, efficient, and less reliant on serendipity. This viewpoint is not intended to be a comprehensive review of contributing literature and was written with a focus on bacteria. Strategies to discover NPs from microbial libraries, including a variety of genomics and "OSMAC" style approaches, are considered downstream of sample collection and library creation, and thus are out of the scope of this viewpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.